Royalty Pharma delivers strong momentum with Q1 results. Portfolio Receipts increased 10% to $925 million while Royalty Receipts grew 13% to $887 million, confirming broad-based growth. The company's 2030 Portfolio Receipts target of $4.7 billion appears increasingly conservative given recent funding agreements with Johnson & Johnson and prior collaborations with Biogen, Merck, and Teva. Management's strategic positioning in the pharmaceutical royalty space strengthens as capital flexibility and share buybacks provide meaningful tailwinds. The stock has delivered over 100% total return since 2023, reflecting strong execution and pipeline expansion that positions the company well for sustained growth ahead.
Post from MarketNews_en
Log in to interact with content.